WVU and Pitt team up for laser trial to treat glaucoma
(West Virginia University) Dr. Tony Realini, professor of ophthalmology and glaucoma specialist at WVU, will be the principal investigator of a $15.2 million study on how a treatment called selective laser trabeculoplasty (SLT) can be better used to treat glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 24, 2020 Category: International Medicine & Public Health Source Type: news
15-minute laser is best treatment for glaucoma patients, says study
Top surgeon hails fast procedure that saves a lifetime using eye dropsLasers should become the principal method in the UK for treating patients with the debilitating eye condition glaucoma. That is the stark conclusion of a three-year study published on Sunday.The report, which appears in theLancet, says the laser technique – known as selective laser trabeculoplasty or SLT – should replace the prescribing of eye drops, the current favoured way to treat glaucoma. The study has revealed that SLT is not only more effective and safer, but should also save the NHS £1.5m a year in tackling the condition.Continu...
Source: Guardian Unlimited Science - March 9, 2019 Category: Science Authors: Robin McKie science editor Tags: Health NHS Society Science Source Type: news
Glaukos wins FDA nod for IDE trial of iStent SA
Glaukos (NYSE:GKOS) said today it won FDA investigational device exemption to launch a pivotal study of its iStent SA trabecular micro-bypass system designed to treat glaucoma. The San Clemente, Calif.-based company’s iStent SA is designed to reduce intraocular pressure in psuedophakic, mild-to-moderate open-angle, pigmentary or psuedoexfoliative glaucoma patients, the company said. The system includes 2 micro-scale titanium stents in an auto-injection system which can be injected into trabecular meshwork locations through a single corneal entry point to restore physiological outflow of aqueous humor into the Sc...
Source: Mass Device - December 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Source Type: news
Allergan gel-based stents are treating glaucoma
[Image from University of Michigan]An Allergan-developed gelatin-based stent is showing potential to treat glaucoma in a quicker and safer environment, according to new research from the University of Michigan. Glaucoma is a disease that damages the eye’s optic nerve and can cause vision loss and blindness. Medicines in the form of eyedrops or pills can be used to treat glaucoma. Another option is laser trabeculoplasty which helps drain fluid from the eye. Conventional surgery also creates a new opening in the eye for fluid to leave. Both surgical options are invasive and prone to complications. With the amount of gl...
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Stents Surgical Allergan Inc. Glaucoma MedTech Source Type: news
Glaukos touts economic savings in dual iStent study
Glaukos (NYSE:GKOS) today touted data from an economic analysis of elevated intraocular pressure treatments in open-angle glaucoma patients, which reported low cost associated with the use of its iStent devices. The economic analysis study aimed to analyze direct cost for 3 treatment options for treating patients with elevated IOP open-angle glaucoma, including selective laser trabeculoplasty, topical glaucoma medication and the use of 2 iStent trabecular micro-bypass stents. Results indicated a lower projected average cumulative cost at 5 years with the use of 2 iStent devices when compared to the other treatment opt...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news
Open-Angle Glaucoma Treated With MicroPulse LaserOpen-Angle Glaucoma Treated With MicroPulse Laser
How does MicroPulse laser trabeculoplasty compare with argon laser trabeculoplasty and selective laser trabeculoplasty in the treatment of open-angle glaucoma? Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 19, 2016 Category: Opthalmology Tags: Ophthalmology Viewpoint Source Type: news
Repeat Laser Trabeculoplasty for Intraocular Pressure ControlRepeat Laser Trabeculoplasty for Intraocular Pressure Control
In eyes with open-angle glaucoma that have already had successful initial selective laser trabeculoplasty (SLT), repeat SLT can restore intraocular pressure (IOP) control, new research suggests. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 17, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Selective Laser Trabeculoplasty for Normal Tension GlaucomaSelective Laser Trabeculoplasty for Normal Tension Glaucoma
At twelve months, patients with normal tension glaucoma sustained IOP reduction and less medication use after one session of selective laser trabeculoplasty. BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 5, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Brian Walsh looks to transcend glaucoma treatment with CyPass micro-stent
Transcend Medical CEO Brian Walsh tells MassDevice.com why his company's CyPass micro-stent is poised to revolutionize the treatment of glaucoma. Until recently, the treatment for glaucoma – a group of diseases that cause pressure within the eyeball – consisted of several options, none of them ideal. Patients could opt for medicines, either oral or via eyedrops, to lower eye pressure. A surgical option that in essence creates a drain in the eyeball for ocular fluid is also available, as is a procedure call laser trabeculoplasty that also creates a drainage pathway. Transcend Medical Inc.News Well, ...
Source: Mass Device - June 2, 2014 Category: Medical Equipment Authors: Brad PerrielloBrad Perriello Source Type: news
Low-Power Annual SLT Effective for Ocular HypertensionLow-Power Annual SLT Effective for Ocular Hypertension
Improvement was greater with a regimen of yearly low-power selective laser trabeculoplasty (SLT) treatments than with standard SLT therapy. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
SLT Shows Benefit for Glaucoma in Afro-Caribbean PatientsSLT Shows Benefit for Glaucoma in Afro-Caribbean Patients
St. Lucian patients receiving just 1 selective laser trabeculoplasty (SLT) treatment session as monotherapy showed significant reductions in intraocular pressure lasting 3 years. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news